A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors

Protocol: 
AAAQ6730
Phase: 
I

A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer stem cells, in addition to the remaining cancer cells, and it may also prevent the growth of new blood vessels that tumors need to grow and spread. Demcizumab, used in this study, is experimental.

Are you Eligible? (Inclusion Criteria)

1. Measurable disease per RECIST v1.1
2. Availability of FFPE tumor tissue, either fresh core-needle-biopsied or
archived.
3. Age >21 years
4. ECOG performance status of 0 or 1

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States